FDA sends warning letter to UK CBD company over coronavirus claims

The U.S. Food and Drug Administration has issued a warning letter to a CBD manufacturer based in the UK for making claims that its products could prevent or treat coronavirus infections.

The letter was sent to London-based Nova Botanix LTD, which sells CBD products under the brand CanaBD, on Thursday.

It was the latest in a series of FDA warning letters sent to CBD manufacturers and retailers in connection with Covid-19 claims.

Because the CanaBD website offers CBD products for sale in the United States, the FDA said the company’s claims violated U.S. regulations and warranted the warning letter.

The FDA cited statements made on the CanaBD website that “finding relief from an incurable virus is just within reach in the form of CBD oil,” and that “CBD oil may help to prevent getting infected by strengthening your immune system” and “has also been proven to offer relief to some of the symptoms.”

The letter gave the company 48 hours to respond with the actions it has taken to correct the violations or else risk legal action.

Nova Botanix did not immediately responded to request for comment from Hemp Industry Daily on the warning.